Brain and blood DNA methylation profiling in Machado-Joseph disease (MJD)/spinocerebellar ataxia type 3 (SCA3)
This study provides the first integrated analysis of DNA methylation in Machado-Joseph disease, revealing that while brain alterations are subtle, region-specific, and enriched for myelination pathways, peripheral blood methylation changes are limited, do not mirror brain findings, and are more pronounced in preclinical carriers.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is a complex machine, but its instruction manual is not just the DNA sequence we inherit at birth. There is a second layer of instruction, a chemical system that sits on top of the genetic code and decides which genes are turned on or off. This system, known as epigenetics, acts like a set of volume knobs for our genes, allowing the same DNA to function differently in the brain compared to the blood, or to change as we age. One of the most common ways this system works is through DNA methylation, a process where tiny chemical tags are added to the DNA molecule. These tags do not change the letters of the genetic code itself, but they can silence a gene or make it more active, influencing how cells behave and how diseases develop.
Machado-Joseph disease, also known as spinocerebellar ataxia type 3, is a devastating condition that causes the brain to slowly lose its ability to control movement. It is caused by a specific error in a single gene, where a short sequence of genetic letters is repeated too many times. While scientists know the genetic cause, they do not fully understand why the disease affects people so differently. Some patients show symptoms in their thirties, while others do not develop them until their seventies, and the severity of the condition varies widely even among family members with the same genetic error. This suggests that factors beyond the DNA sequence itself, such as these epigenetic tags, might be shaping the course of the illness. Understanding these chemical changes could reveal new ways to track the disease or even develop treatments that work by adjusting the volume of specific genes.
A team of researchers set out to map these chemical tags in people with Machado-Joseph disease to see if they could find a pattern that explains the disease's behavior. They looked at two very different places in the body: the brain, where the disease causes its most severe damage, and the blood, which is much easier to sample and might show if the disease has effects throughout the whole body. For the brain study, they examined tissue from six people who had died from the disease and six healthy individuals who served as a comparison. They focused on two specific areas of the brain: the dentate nucleus, a deep structure that is heavily damaged in this condition, and the cerebral cortex, the outer layer of the brain that remains relatively healthy. For the blood study, they analyzed samples from twenty-four people carrying the disease gene, including those who had already developed symptoms and those who were carriers but had not yet shown any signs of the illness.
The researchers found that the chemical tags in the brain were not scattered randomly across individual genes. Instead, the changes were subtle and occurred in broad stretches of the genetic code. In the deeply damaged dentate nucleus, they identified forty-four distinct regions where the chemical tags differed between patients and healthy people. In the healthier cerebral cortex, they found even more changes, with one hundred and thirty-one regions showing differences. Interestingly, the changes in the healthy part of the brain were more numerous and often involved genes related to the maintenance of myelin, the protective coating around nerve fibers that helps signals travel quickly. This suggests that even in areas that look healthy under a microscope, the chemical instructions for keeping nerve fibers intact might be under stress. However, when the researchers looked for a single, specific pattern of chemical tags in the blood that could serve as a unique fingerprint for the disease, they found nothing. The blood samples did not show a distinct signature that separated the patients from the healthy controls, indicating that the chemical changes in the blood do not simply mirror what is happening in the brain.
Despite the lack of a blood fingerprint, the study revealed that the chemical tags in the blood do change as the disease progresses. The researchers discovered that the length of time a person had been living with the disease was linked to specific changes in the methylation patterns of their blood cells. People who had been sick for a longer time showed different chemical tag levels compared to those who had been sick for a shorter time. This suggests that the disease leaves a trace in the blood that evolves over time, even if it does not create a static signature. Furthermore, the study found that people who carried the disease gene but had not yet developed symptoms showed more chemical changes in their blood than those who were already sick. This counterintuitive finding implies that the body's chemical response to the genetic error might be most active in the early stages, before the physical symptoms become apparent.
The researchers also investigated whether the disease made people biologically older than they actually were. They used a method that estimates biological age based on the pattern of chemical tags on DNA. While both the patients and the healthy people showed signs of being slightly older than their calendar age, the disease itself did not seem to accelerate this aging process in the blood. The study concluded that the chemical changes in Machado-Joseph disease are complex and highly specific to the tissue where they occur. The brain shows region-specific alterations, particularly in the healthy parts of the brain where myelin maintenance is affected, while the blood shows changes that are linked to the duration of the illness rather than a fixed disease signature. These findings provide the first integrated view of how this disease alters the chemical instructions in the body, offering a clearer picture of the molecular landscape that researchers must navigate to understand and treat this condition.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.